Skip to main content

Table 1 Summary of main urinary markers

From: Recent advances in the diagnosis and treatment of bladder cancer

Markers Overall sensitivity, % Overall specificity, % Sensitivity for high-grade tumors, % Point-of-care test Interferenceb Comments
Aneuploidy detection kitc 30 to 72 63 to 95 66 to 70 No No Expensive and laborious
Microsatellite analysis 58 73 90 No No Expensive and laborious
Gene microarray 80 to 90 62 to 65 80 No No Expensive and laborious
Monoclonal antibodiesd 76 to 85 63 to 75 67 to 92 No Yes Good sensitivity in low-grade tumors, affected by BCG
NMP 22 49 to 68 85.8 to 87.5 75 to 83 Yes Yes Low sensitivity, affected by benign conditions
Physician-use BTA immunoassaye 57 to 83 68 to 85.7 61.5 Yes Yes Low sensitivity, affected by benign conditions and BCG
Quantitative laboratory BTA immunoassayf 53 to 91 28 to 83 77 No Yes Low sensitivity, affected by benign conditions and BCG
Cytokeratins 12 to 85 75 to 97 33 to 82 No Yes Low sensitivity, affected by benign conditions and BCG
Survivin 53 to 90 88 to 100 50 No No Low sensitivity, expensive and laborious
  1. Abbreviations: BCG, bacille Calmette-Guérin; BTA, bladder tumor-associated antigen; NMP, nuclear matrix protein
  2. aAdapted from Expert Review of Anticancer Therapy, June 2010, Vol. 10, No. 6, Pages 787-790 with permission of Expert Reviews Ltd.
  3. bBy BCG instillations and other bladder conditions.
  4. cUroVysion®; Abbott Molecular Inc , Des Plaines, IL, USA.
  5. dImmunocyt/uCyt+™; DiagnoCure Inc., Québec, Canada.
  6. eBTA stat ®; Polymedco Inc., Cortlandt Manor, NY, USA.
  7. fBTA TRAK™; Polymedco Inc.